Brief: Stoke Therapeutics Announces New Safety & Efficacy Data For Stk-001 Studies

Stoke Therapeutics

25/07/2023 12:33

July 25 (Reuters) - Stoke Therapeutics Inc  STOK.O :
    * STOKE THERAPEUTICS ANNOUNCES POSITIVE NEW SAFETY &
EFFICACY DATA
FROM PATIENTS TREATED WITH STK-001 IN THE PHASE 1/2A STUDIES
(MONARCH & ADMIRAL) AND THE SWALLOWTAIL OPEN-LABEL EXTENSION
(OLE) STUDY IN CHILDREN AND ADOLESCENTS WITH DRAVET SYNDROME
    * STOKE THERAPEUTICS INC - ADDITIONAL DATA ANTICIPATED IN Q1
2024
FOLLOWING COMPLETION OF PHASE 1/2A STUDIES
    * STOKE THERAPEUTICS INC - STK-001 HAS BEEN GENERALLY
WELL-TOLERATED AMONG 74 PATIENTS TREATED WITH SINGLE AND
MULTIPLE DOSES OF 10MG TO 70MG

Source text for Eikon:  ID:nBw2Tn46Ma 
Further company coverage:  STOK.O 

 ((Reuters.Briefs@thomsonreuters.com;))